US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apogee Therapeutics

40.98

+3.338.84%

Post-market: 40.980.00000.00%16:28 EDT

Volume:1.11M

Turnover:45.62M

Market Cap:2.39B

PE:-11.41

High:42.50

Open:38.45

Low:38.39

Close:37.65

Loading ...

Overview Company News Filings

Apogee Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $95

THOMSON REUTERS

Apogee Therapeutics initiated with a Buy at Citi

Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments

Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position

Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments

Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress

Apogee Therapeutics Shares Rise After Positive Interim Results

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Apogee Therapeutics price target raised to $116 from $110 at Guggenheim

Apogee Therapeutics Reports Positive Phase 1 Results

Apogee Therapeutics Full-Year Loss Widens

MT Newswires Live

Apogee Therapeutics says cash sufficient to fund expenses into 1Q28

Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss

MT Newswires Live

Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M

MT Newswires Live

BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial

Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics Inc - Apg990 Well Tolerated up to 1,200Mg Doses

THOMSON REUTERS

Apogee Therapeutics Announces Positive Interim Phase 1 Results From the Apg990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for Apg279 (Apg777 + Apg990)

THOMSON REUTERS

Apogee Therapeutics Inc - No Severe Adverse Events or Study Discontinuations for Apg990

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/APGE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":40.98,"timestamp":1749240000000,"preClose":37.65,"halted":0,"volume":1112592,"hourTrading":{"tag":"盘后","latestPrice":40.98,"preClose":40.98,"latestTime":"16:28 EDT","volume":42824,"amount":1754927.52,"timestamp":1749241706952},"delay":0,"floatShares":37589079,"shares":58368834,"eps":-3.591044,"marketStatus":"Market Closed","change":3.33,"latestTime":"06-06 16:00:00 EDT","open":38.45,"high":42.4999,"low":38.39,"amount":45618259.055816,"amplitude":0.109161,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.591044,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":37.65,"preHourTrading":{"tag":"盘前","latestPrice":37.97,"preClose":37.65,"latestTime":"08:40 EDT","volume":4,"amount":151.88,"timestamp":1749213617264},"postHourTrading":{"tag":"盘后","latestPrice":40.98,"preClose":40.98,"latestTime":"16:28 EDT","volume":42824,"amount":1754927.52,"timestamp":1749241706952},"volumeRatio":1.2972026113972672,"impliedVol":1.8149,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","floatShares":37589079,"roa":"-19.65%","roe":"-27.85%","lyrEps":-3.300106,"volumeRatio":1.2972026113972672,"shares":58368834,"dividePrice":0,"high":42.4999,"amplitude":0.109161,"preClose":37.65,"low":38.39,"week52Low":26.2,"pbRate":"3.55","week52High":63.5,"institutionHeld":0,"latestPrice":40.98,"eps":-3.591044,"divideRate":0,"volume":1112592,"delay":0,"ttmEps":-3.591044,"open":38.45,"prevYearClose":45.3,"prevWeekClose":36.64,"prevMonthClose":36.64,"prevQuarterClose":37.36,"fiveDayClose":36.64,"twentyDayClose":37.81,"sixtyDayClose":38.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APGE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519846458","title":"Apogee Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2519846458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519846458?lang=en_us&edition=fundamental","pubTime":"2025-03-13 18:30","pubTimestamp":1741861852,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW10L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2519881071","title":"Apogee Therapeutics initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2519881071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519881071?lang=en_us&edition=fundamental","pubTime":"2025-03-13 18:16","pubTimestamp":1741860965,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $95 price target Healthcare policy remains a key biopharma sector uncer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-initiated-with-a-buy-at-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-initiated-with-a-buy-at-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2518206282","title":"Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206282","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518206282?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:15","pubTimestamp":1741630513,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on March 4. Tyler Van Buren has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strong-buy-recommendation-for-apogee-therapeutics-driven-by-promising-clinical-data-and-strategic-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strong-buy-recommendation-for-apogee-therapeutics-driven-by-promising-clinical-data-and-strategic-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2517994209","title":"Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2517994209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517994209?lang=en_us&edition=fundamental","pubTime":"2025-03-05 18:19","pubTimestamp":1741169952,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tim Anderson has maintained their bullish stance on APGE stock, giving a Buy rating on March 3. Tim Anderson has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/apogee-therapeutics-buy-rating-backed-by-promising-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/apogee-therapeutics-buy-rating-backed-by-promising-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2516678336","title":"Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2516678336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516678336?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:56","pubTimestamp":1741089414,"startTime":"0","endTime":"0","summary":"Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Apogee Therapeutics (APGE – Research Report), with a price target of $89.00. Ed...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-apogee-therapeutics-driven-by-promising-clinical-trial-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-apogee-therapeutics-driven-by-promising-clinical-trial-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2516616230","title":"Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2516616230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516616230?lang=en_us&edition=fundamental","pubTime":"2025-03-04 12:02","pubTimestamp":1741060955,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics, Inc. ( ($APGE) ) has released its Q4 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BK4139","BK4097","LU2065732104.USD","APGE"],"gpt_icon":0},{"id":"2516498659","title":"Apogee Therapeutics Shares Rise After Positive Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516498659","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516498659?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:31","pubTimestamp":1741023060,"startTime":"0","endTime":"0","summary":"Shares of Apogee Therapeutics advanced after sharing positive interim results that push forward more trials of inflammatory and immunology treatments.The stock rose 6% to $33.37 on Monday. Shares have lost about a quarter of their value in 2025.The biotechnology company reported positive interim results for the Phase 1 of APG990, a product that, when combined with another product called APG777, could treat several inflammatory and immunology diseases including asthma and atopic dermatitis.Data from its Phase 1 trial for APG777 showed consistent safety results and supports the ongoing Phase 2 clinical trial, Apogee said.Based on the data, Apogee plans to start its first combination trial of APG777 and APG990 used together, in 2025.Apogee said it has enough existing cash, cash equivalents and securities to fund operations into the first quarter of 2028.It had a loss of $182.1 million in 2024, compared with a loss of $84 million the prior year. The company said it has been spending more o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516752656","title":"Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752656","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752656?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:16","pubTimestamp":1741022203,"startTime":"0","endTime":"0","summary":"On Monday, Apogee Therapeutics, Inc.  released interim Phase 1 results from its first-in-human trial of APG990.APG990 interim Phase 1 pharmacokinetic  data showed a half-life of approximately 60 days across doses tested.Key data from the 40-healthy subject trial showed:. APG990 demonstrated a potential best-in-class PK profile, including a half-life of approximately 60 days, supporting the potential for every three- and six-month maintenance dosing. The PK profile supports the potential for a single 2 mL co-formulated injection of APG279  administered every three and six months.APG990 was well tolerated across all five cohorts, with doses up to 1,200mg. The most common  treatment-emergent adverse events  were headache.53% of participants observed at least one TEAE.In addition, preclinical studies of the combination of APG777 and APG990 showed potential for enhanced pharmacologic responses relative to individual agents and exhibited no safety findings at any dose level, including the hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-investigational-atopic-dermatitis-171643556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","USJW.SI","APGE","LU0289739699.SGD","BK4181","BK4139","PSQ","MNQmain","LU0882574055.USD",".IXIC","LU0058720904.USD","BK4588","LU2023250504.SGD","REGN","LU2089984988.USD","SQQQ","LU2468319806.SGD","LU0823416689.USD","LU0109394709.USD","QLD","BK4007","LU1917777945.USD","NVIW.SI","LU0320765992.SGD","BK4585","USAW.SI","LU1974910355.USD","IE00BFXG1179.USD","TSYW.SI","LU2362541273.HKD","SNY","QID","TQQQ","LU0053666078.USD","LU0889565916.HKD","LU2362540622.SGD","PK","NQmain","LU2362541513.USD","LU2237438978.USD","LU2106854487.HKD","LU0114720955.EUR"],"gpt_icon":1},{"id":"2516350746","title":"Apogee Therapeutics price target raised to $116 from $110 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2516350746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516350746?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:31","pubTimestamp":1741008663,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics (APGE) to $116 from $110 and keeps a Buy rating on the sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-price-target-raised-to-116-from-110-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-price-target-raised-to-116-from-110-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2516094680","title":"Apogee Therapeutics Reports Positive Phase 1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516094680","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516094680?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:29","pubTimestamp":1741004968,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics ( ($APGE) ) has issued an update. On March 3, 2025, Apogee Therapeutics announced positive interim Phase 1 results from its fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-positive-phase-1-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-positive-phase-1-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516682668","title":"Apogee Therapeutics Full-Year Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2516682668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516682668?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:34","pubTimestamp":1741001675,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics  reported a 2024 net loss Monday of $182.1 million, widening from a loss of $84 million a year earlier.Analysts polled by FactSet expected a loss of $177.9 million.At the end of the year, cash, cash equivalents and marketable securities were $731.1 million. The company said it expects its existing cash, cash equivalents and marketable securities to allow it to fund its operating expenses into Q1 2028.Apogee shares were up 1.5% in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516823136","title":"Apogee Therapeutics says cash sufficient to fund expenses into 1Q28","url":"https://stock-news.laohu8.com/highlight/detail?id=2516823136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516823136?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:25","pubTimestamp":1741001137,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities were $731.1M as of December 31, 2024, compared to $395.5M as of December 31, 2023. Based on curren...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-says-cash-sufficient-to-fund-expenses-into-1q28?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-says-cash-sufficient-to-fund-expenses-into-1q28?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516684698","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684698?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:15","pubTimestamp":1741000528,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"gpt_icon":0},{"id":"2516684660","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684660?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:15","pubTimestamp":1741000513,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","APGE"],"gpt_icon":0},{"id":"2516001681","title":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516001681","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516001681?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:10","pubTimestamp":1741000231,"startTime":"0","endTime":"0","summary":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer TrialMarch 3 (Reuters) - Apogee Therapeutics APGE.O:APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516848236","title":"Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2516848236","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516848236?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:07","pubTimestamp":1741000067,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44072233/apogee-therapeutics-says-cash-cash-equivalents-and-marketable-securities-of-731-1m-as-of-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516684183","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684183","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684183?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:05","pubTimestamp":1740999900,"startTime":"0","endTime":"0","summary":"Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035381/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","PRGS","APGE","LU1169590202.USD","PD","BK4097","LU1169589451.USD","LU2065732104.USD","PK","BK4023","TSLP","BK4218","BK4139"],"gpt_icon":0},{"id":"2516814196","title":"Apogee Therapeutics Inc - Apg990 Well Tolerated up to 1,200Mg Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2516814196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516814196?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516681966","title":"Apogee Therapeutics Announces Positive Interim Phase 1 Results From the Apg990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for Apg279 (Apg777 + Apg990)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516681966?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516681494","title":"Apogee Therapeutics Inc - No Severe Adverse Events or Study Discontinuations for Apg990","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516681494?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":55,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"APGE","fiscalQuarterEnding":"2025/03","expectedEps":-1.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.95},{"market":"US","date":"2025-03-03","symbol":"APGE","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2024-11-12","symbol":"APGE","fiscalQuarterEnding":"2024/09","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7778,"buy":0.2222,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7778,"analysts":9,"updateTime":1741924800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APGE","date":"2025-06-06","current":-10.699527,"percent":0.951435,"low":-42.099968,"twenty":-26.74614,"median":-20.193343,"eighty":-12.998374,"high":-9.181289,"avg":-20.957073,"sd":7.856766,"marketCap":2197586600},"quantilePoints":[{"date":"2023-07-14","current":-14.120082,"twenty":-14.120082,"median":-14.120082,"eighty":-14.120082,"marketCap":728904256},{"date":"2023-07-21","current":-18.011929,"twenty":-18.356106,"median":-18.157543,"eighty":-18.011929,"marketCap":929808491},{"date":"2023-07-28","current":-20.899222,"twenty":-20.280785,"median":-18.735584,"eighty":-18.04723,"marketCap":1078855761},{"date":"2023-08-04","current":-20.732342,"twenty":-20.732342,"median":-20.114656,"eighty":-18.267856,"marketCap":1070241131},{"date":"2023-08-11","current":-21.547107,"twenty":-20.865853,"median":-20.262175,"eighty":-18.356106,"marketCap":1112300797},{"date":"2023-08-18","current":-23.166822,"twenty":-21.272247,"median":-20.482022,"eighty":-18.735584,"marketCap":1195913385},{"date":"2023-08-25","current":-24.246631,"twenty":-22.764347,"median":-20.836643,"eighty":-19.947026,"marketCap":1251655111},{"date":"2023-09-01","current":-16.923199,"twenty":-22.901778,"median":-20.784492,"eighty":-18.356106,"marketCap":1162468350},{"date":"2023-09-08","current":-17.424846,"twenty":-22.791833,"median":-20.482022,"eighty":-18.04017,"marketCap":1196926871},{"date":"2023-09-15","current":-15.33711,"twenty":-22.261745,"median":-20.262175,"eighty":-17.454355,"marketCap":1053518613},{"date":"2023-09-22","current":-15.742854,"twenty":-21.87694,"median":-20.07464,"eighty":-16.946806,"marketCap":1081389476},{"date":"2023-09-29","current":-15.255962,"twenty":-21.600116,"median":-18.735584,"eighty":-16.181057,"marketCap":1047944441},{"date":"2023-10-06","current":-15.816626,"twenty":-21.327219,"median":-18.248406,"eighty":-15.736952,"marketCap":1086456906},{"date":"2023-10-13","current":-14.754315,"twenty":-21.232981,"median":-18.011929,"eighty":-15.43744,"marketCap":1013485920},{"date":"2023-10-20","current":-14.732183,"twenty":-21.097514,"median":-17.509684,"eighty":-15.343012,"marketCap":1011965691},{"date":"2023-10-27","current":-11.065736,"twenty":-21.032725,"median":-17.443289,"eighty":-15.295798,"marketCap":760114440},{"date":"2023-11-03","current":-13.714136,"twenty":-20.892548,"median":-17.107628,"eighty":-15.064155,"marketCap":942035162},{"date":"2023-11-10","current":-11.751812,"twenty":-20.860011,"median":-16.901067,"eighty":-14.764643,"marketCap":807241535},{"date":"2023-11-17","current":-12.191046,"twenty":-20.815783,"median":-16.340404,"eighty":-14.242502,"marketCap":851834915},{"date":"2023-11-24","current":-12.473884,"twenty":-20.732342,"median":-15.9863,"eighty":-13.271633,"marketCap":871597891},{"date":"2023-12-01","current":-14.149156,"twenty":-20.643994,"median":-15.77974,"eighty":-12.959786,"marketCap":988655514},{"date":"2023-12-08","current":-15.76641,"twenty":-20.320051,"median":-15.713345,"eighty":-13.06857,"marketCap":1101659195},{"date":"2023-12-15","current":-16.854248,"twenty":-20.280785,"median":-15.705968,"eighty":-13.227243,"marketCap":1177670639},{"date":"2023-12-22","current":-18.52952,"twenty":-20.262175,"median":-15.76641,"eighty":-13.271633,"marketCap":1294728262},{"date":"2023-12-29","current":-21.77128,"twenty":-20.316166,"median":-15.824003,"eighty":-13.537135,"marketCap":1521242365},{"date":"2024-01-05","current":-20.48763,"twenty":-20.454114,"median":-15.9863,"eighty":-13.786432,"marketCap":1431548862},{"date":"2024-01-12","current":-23.098443,"twenty":-20.721111,"median":-16.285075,"eighty":-14.084509,"marketCap":1613976327},{"date":"2024-01-19","current":-23.34502,"twenty":-20.899222,"median":-16.57141,"eighty":-14.120082,"marketCap":1631205588},{"date":"2024-01-26","current":-26.1734,"twenty":-21.423171,"median":-16.854248,"eighty":-14.149156,"marketCap":1828835342},{"date":"2024-02-02","current":-24.650426,"twenty":-22.136094,"median":-16.901067,"eighty":-14.410237,"marketCap":1722419321},{"date":"2024-02-09","current":-26.833356,"twenty":-22.901778,"median":-17.107628,"eighty":-14.722084,"marketCap":1874948952},{"date":"2024-02-16","current":-25.919571,"twenty":-23.170966,"median":-17.443289,"eighty":-14.732183,"marketCap":1811099339},{"date":"2024-02-23","current":-25.462679,"twenty":-23.458155,"median":-17.594521,"eighty":-14.738085,"marketCap":1779174532},{"date":"2024-03-01","current":-25.252364,"twenty":-23.903055,"median":-18.011929,"eighty":-14.745463,"marketCap":1764478986},{"date":"2024-03-08","current":-39.349598,"twenty":-24.476372,"median":-18.248406,"eighty":-14.75284,"marketCap":3304775976},{"date":"2024-03-15","current":-39.31944,"twenty":-25.034796,"median":-18.52952,"eighty":-14.795627,"marketCap":3302243192},{"date":"2024-03-22","current":-40.133695,"twenty":-25.237859,"median":-19.967125,"eighty":-14.977105,"marketCap":3370628348},{"date":"2024-03-28","current":-41.080642,"twenty":-25.310382,"median":-20.039026,"eighty":-15.024319,"marketCap":3450157751},{"date":"2024-04-05","current":-35.585933,"twenty":-25.583066,"median":-20.203754,"eighty":-15.040549,"marketCap":2988684589},{"date":"2024-04-12","current":-40.39061,"twenty":-25.977589,"median":-20.297181,"eighty":-15.087984,"marketCap":3392205375},{"date":"2024-04-19","current":-33.647243,"twenty":-26.134238,"median":-20.48763,"eighty":-15.119386,"marketCap":2825863713},{"date":"2024-04-26","current":-30.802638,"twenty":-26.87687,"median":-20.704265,"eighty":-15.154157,"marketCap":2586959527},{"date":"2024-05-03","current":-35.061005,"twenty":-31.417884,"median":-20.865853,"eighty":-15.223502,"marketCap":2944598502},{"date":"2024-05-10","current":-35.544605,"twenty":-33.702281,"median":-21.144633,"eighty":-15.273667,"marketCap":2985213654},{"date":"2024-05-17","current":-30.341768,"twenty":-33.2059,"median":-21.423171,"eighty":-15.316454,"marketCap":3142011451},{"date":"2024-05-24","current":-25.989488,"twenty":-32.751748,"median":-21.791716,"eighty":-15.341537,"marketCap":2691315483},{"date":"2024-05-31","current":-26.170128,"twenty":-32.249341,"median":-22.218395,"eighty":-15.347905,"marketCap":2710021411},{"date":"2024-06-07","current":-23.773834,"twenty":-31.497141,"median":-22.764347,"eighty":-15.361417,"marketCap":2461875577},{"date":"2024-06-14","current":-24.341154,"twenty":-31.168024,"median":-22.917136,"eighty":-15.378422,"marketCap":2520623884},{"date":"2024-06-21","current":-21.479149,"twenty":-30.802638,"median":-22.901778,"eighty":-15.396128,"marketCap":2224251827},{"date":"2024-06-28","current":-22.551696,"twenty":-30.67474,"median":-22.901778,"eighty":-15.416784,"marketCap":2335318278},{"date":"2024-07-05","current":-21.168675,"twenty":-30.454668,"median":-22.551696,"eighty":-15.452028,"marketCap":2192101012},{"date":"2024-07-12","current":-25.927394,"twenty":-30.290963,"median":-22.599678,"eighty":-15.490824,"marketCap":2684885320},{"date":"2024-07-15","current":-27.107194,"twenty":-30.240158,"median":-22.64766,"eighty":-15.512581,"marketCap":2807058416},{"date":"2024-08-02","current":-25.825784,"twenty":-30.189354,"median":-22.706004,"eighty":-15.534337,"marketCap":2674363235},{"date":"2024-08-09","current":-22.78314,"twenty":-29.894686,"median":-22.901778,"eighty":-15.586554,"marketCap":2359285249},{"date":"2024-08-16","current":-22.360657,"twenty":-29.660984,"median":-22.773744,"eighty":-15.598555,"marketCap":2649402436},{"date":"2024-08-23","current":-23.604561,"twenty":-29.231009,"median":-22.862169,"eighty":-15.66023,"marketCap":2796786413},{"date":"2024-08-30","current":-24.399278,"twenty":-28.636347,"median":-22.994085,"eighty":-15.707443,"marketCap":2890948398},{"date":"2024-09-06","current":-23.811878,"twenty":-28.151516,"median":-23.098851,"eighty":-15.725149,"marketCap":2821350409},{"date":"2024-09-13","current":-24.28081,"twenty":-27.512504,"median":-23.170966,"eighty":-15.752276,"marketCap":2876911828},{"date":"2024-09-20","current":-26.136794,"twenty":-27.110581,"median":-23.268758,"eighty":-15.786496,"marketCap":3096818079},{"date":"2024-09-27","current":-28.649283,"twenty":-28.484417,"median":-23.34502,"eighty":-15.822528,"marketCap":3394510318},{"date":"2024-10-04","current":-28.061884,"twenty":-28.569318,"median":-23.434542,"eighty":-15.893348,"marketCap":3324912329},{"date":"2024-10-11","current":-26.610663,"twenty":-28.484417,"median":-23.533922,"eighty":-16.011479,"marketCap":3152964356},{"date":"2024-10-18","current":-27.755844,"twenty":-28.448831,"median":-23.612583,"eighty":-16.121447,"marketCap":3288651192},{"date":"2024-10-25","current":-25.643182,"twenty":-28.355515,"median":-23.773834,"eighty":-16.274009,"marketCap":3038332374},{"date":"2024-10-31","current":-27.099339,"twenty":-28.252419,"median":-23.811878,"eighty":-16.385155,"marketCap":3210865204},{"date":"2024-11-08","current":-28.654219,"twenty":-28.465143,"median":-23.860074,"eighty":-16.567059,"marketCap":3395095175},{"date":"2024-11-15","current":-19.789128,"twenty":-28.485404,"median":-23.853973,"eighty":-16.630879,"marketCap":2902332924},{"date":"2024-11-22","current":-16.628998,"twenty":-28.465143,"median":-23.803477,"eighty":-16.671147,"marketCap":2438858722},{"date":"2024-11-29","current":-17.517481,"twenty":-28.399895,"median":-23.76973,"eighty":-16.839744,"marketCap":2569166386},{"date":"2024-12-06","current":-18.297329,"twenty":-28.288946,"median":-23.604561,"eighty":-16.854248,"marketCap":2683541235},{"date":"2024-12-13","current":-17.195455,"twenty":-28.106309,"median":-23.497667,"eighty":-16.861788,"marketCap":2521936971},{"date":"2024-12-20","current":-18.243012,"twenty":-28.061884,"median":-23.417542,"eighty":-16.878936,"marketCap":2675574828},{"date":"2024-12-27","current":-18.305089,"twenty":-28.042139,"median":-23.34502,"eighty":-16.878936,"marketCap":2684679293},{"date":"2025-01-03","current":-18.29345,"twenty":-27.898004,"median":-23.314068,"eighty":-16.905494,"marketCap":2682972206},{"date":"2025-01-10","current":-19.092697,"twenty":-27.799282,"median":-23.175118,"eighty":-16.935003,"marketCap":2800192201},{"date":"2025-01-17","current":-14.239016,"twenty":-27.785817,"median":-23.13304,"eighty":-16.857264,"marketCap":2088336797},{"date":"2025-01-24","current":-15.60084,"twenty":-27.774326,"median":-23.084739,"eighty":-16.58873,"marketCap":2288066011},{"date":"2025-01-31","current":-16.489324,"twenty":-27.755844,"median":-22.901778,"eighty":-16.251878,"marketCap":2418373675},{"date":"2025-02-07","current":-16.155657,"twenty":-27.743997,"median":-22.822654,"eighty":-16.03771,"marketCap":2369437172},{"date":"2025-02-14","current":-14.068303,"twenty":-27.666994,"median":-22.64766,"eighty":-15.83959,"marketCap":2063299516},{"date":"2025-02-21","current":-13.17206,"twenty":-27.548527,"median":-22.532767,"eighty":-15.742854,"marketCap":1931853794},{"date":"2025-02-28","current":-11.845154,"twenty":-27.262231,"median":-22.345048,"eighty":-15.697836,"marketCap":1737245842},{"date":"2025-03-07","current":-11.30201,"twenty":-27.112839,"median":-22.212997,"eighty":-15.60472,"marketCap":2058615932},{"date":"2025-03-14","current":-12.223647,"twenty":-27.107194,"median":-21.977899,"eighty":-15.577851,"marketCap":2226488393},{"date":"2025-03-21","current":-12.874214,"twenty":-27.104275,"median":-21.832491,"eighty":-15.410728,"marketCap":2344986602},{"date":"2025-03-28","current":-12.51704,"twenty":-27.099339,"median":-21.774807,"eighty":-15.344488,"marketCap":2279928762},{"date":"2025-04-04","current":-11.158503,"twenty":-27.089467,"median":-21.479149,"eighty":-15.267174,"marketCap":2032476621},{"date":"2025-04-11","current":-9.54803,"twenty":-27.02252,"median":-21.347709,"eighty":-15.123173,"marketCap":1739135468},{"date":"2025-04-17","current":-10.217731,"twenty":-27.018004,"median":-21.19592,"eighty":-15.044975,"marketCap":1861118918},{"date":"2025-04-25","current":-11.815448,"twenty":-27.009303,"median":-21.066101,"eighty":-14.75284,"marketCap":2152136576},{"date":"2025-05-02","current":-12.501095,"twenty":-26.955194,"median":-20.851248,"eighty":-14.659715,"marketCap":2277024394},{"date":"2025-05-09","current":-12.057816,"twenty":-26.905994,"median":-20.676189,"eighty":-14.171382,"marketCap":2196282968},{"date":"2025-05-16","current":-11.538128,"twenty":-26.893009,"median":-20.509211,"eighty":-14.009329,"marketCap":2369827680},{"date":"2025-05-23","current":-11.469666,"twenty":-26.845089,"median":-20.320051,"eighty":-13.400194,"marketCap":2355766140},{"date":"2025-05-30","current":-10.709474,"twenty":-26.800437,"median":-20.280785,"eighty":-13.20517,"marketCap":2199629509},{"date":"2025-06-06","current":-10.699527,"twenty":-26.74614,"median":-20.193343,"eighty":-12.998374,"marketCap":2197586600}],"updateTime":1749378120258}}}